|
Re: Blinded Sub Group Data; post by Aureus on IV
|
7
|
Resverlogix Corp.
|
Oct 04, 2018 01:20PM
|
|
Re: Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
7
|
Zenith Epigenetics
|
Sep 04, 2018 09:46AM
|
|
Re: Trials don't always work out...
|
7
|
Resverlogix Corp.
|
Mar 02, 2016 07:24PM
|
|
Re: AHA late breaking abstract
|
7
|
Resverlogix Corp.
|
Nov 10, 2019 12:55PM
|
|
DESIGN AND CHARACTERIZATION OF NOVEL COVALENT BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITORS TARGETING A METHIONINE
|
7
|
Zenith Epigenetics
|
Sep 04, 2018 10:23AM
|
|
Re: 2019 Potential Events
|
7
|
Resverlogix Corp.
|
Sep 17, 2019 10:55AM
|
|
BET proteins, NFkB and Diabetic Kidney Disease
|
7
|
Resverlogix Corp.
|
Nov 05, 2018 03:54PM
|
|
Re: ... time lines and yet to come...
|
7
|
Resverlogix Corp.
|
Aug 15, 2018 04:13PM
|
|
Re: It's Time For Zenith To Disclose
|
7
|
Zenith Epigenetics
|
Jan 31, 2017 10:01AM
|
|
3 Resverlogix trials recently updated on ClinicalTrials.gov
|
7
|
Resverlogix Corp.
|
Jan 24, 2019 12:07PM
|
|
What would a successful BETonMACE Top-Line Data Announcement Look Like?
|
7
|
Resverlogix Corp.
|
Aug 10, 2019 12:01PM
|
|
Re: Just back from IR,...
|
7
|
Resverlogix Corp.
|
Oct 25, 2019 11:03PM
|
|
RVX abstract for IDF 2015 World Diabetes Congress
|
7
|
Resverlogix Corp.
|
Nov 16, 2015 01:36PM
|
|
AACR 2020 Poster
|
7
|
Zenith Epigenetics
|
Jun 29, 2020 07:21AM
|
|
Re: Pfizer enzalutimide perspective
|
7
|
Zenith Epigenetics
|
May 16, 2017 10:49AM
|
|
Re: Is rosuvastatin synergy still a going theory?
|
7
|
Resverlogix Corp.
|
Feb 20, 2020 09:07PM
|
|
No ESC 2019 Late Breaker
|
7
|
Resverlogix Corp.
|
Jun 26, 2019 09:25AM
|
|
Re: Key Dates Over the Next Four Months
|
7
|
Resverlogix Corp.
|
Jul 21, 2019 10:32AM
|
|
Re: Good post SanFran
|
7
|
Zenith Epigenetics
|
May 29, 2019 02:11PM
|
|
Re: MD&A... Phase 3 European Regulatory Approval
|
7
|
Resverlogix Corp.
|
Jul 27, 2015 02:27PM
|
